Table 2.
Univariate analysis of clinicopathological factors and inflammatory indexes according to progression-free survival (PFS), overall survival (OS), and Choi response.
| Characteristics | Median PFS (95% CI) | p-Value | Median OS (95% CI) | p-Value | Choi Response (%) | p-Value |
|---|---|---|---|---|---|---|
| Age (years): | 0.94 | 0.18 | 0.46 | |||
| 0–63 | 0.8 (6.7–12.9) | NR | 20 (61%) | |||
| >63 | 7.1 (3.1–11.1) | 49.8 (13.6–85.9) | 16 (50%) | |||
| Sex: | 0.4 | 0.34 | 1 | |||
| Male | 10.5 (8.5–12.5) | NR | 16 (57%) | |||
| Female | 7.1 (3.9–10.4) | 49.8 (NA) | 20 (54%) | |||
| Tumour size (mm) at diagnosis: | ||||||
| 0–85 | 11 (5.7–16.3) | 0.14 | NR | <0.001 | 16 (48%) | 0.32 |
| >85 | 8.1 (4.5–11.8) | 20.8 (10.6–31) | 20 (62%) | |||
| Necrosis: | 0.002 | 0.86 | ||||
| No | 10.5 (8–13) | NR | 30 (58%) | 0.33 | ||
| Yes | 4 (0.8–7.1) | 49.8 (NA) | 4 (40%) | |||
| MFI (months): | 0.011 | 0.15 | <0.001 | |||
| 0–8 | 5.6 (3.5–7.8) | NR | 10 (30%) | |||
| >8 | 11.2 (9.2–13.2) | 49.8 (14.1–85.4) | 26 (81%) | |||
| ECOG: | 0.087 | 0.001 | ||||
| 0 | 10.6 (8.8–12.3) | NR | 23 (66%) | 0.085 | ||
| 1–2 | 7.4 (4.7–10.1) | 18.4 (9.8–26.9) | 13 (43%) | |||
| Number of mitoses (per 10 hpf): | ||||||
| 0–3 | 11.2 (8.7–13.6) | <0.001 | 50 (8.7–90.8) | 0.94 | 21 (58%) | 0.61 |
| >3 | 5.6 (4.4–6.7) | NR | 13 (50%) | |||
| NLR: | 0.01 | <0.001 | 0.18 | |||
| 0–3.78 | 10.8 (8.7–12.9) | NR | 26 (62%) | |||
| >3.78 | 4.5 (1.9–7) | 11.7 (3.5–19.8) | 9 (43%) | |||
| PLR: | 0.005 | <0.001 | ||||
| 0–242 | 10.1 (6.32–13.9) | 49.8 (14.6–85) | 30 (58%) | 0.35 | ||
| >242 | 4.5 (2–7) | 10.7 (5.2–16.2) | 5 (42%) | |||
| RDW: | 0.001 | <0.001 | 0.029 | |||
| 0–1.03 | 9.8 (7.4–12.3) | 49.8 (9.4–90.2) | 25 (59%) | |||
| >1.03 | 4.0 (0.9–7) | 10.7 (3.8–17.5) | 3 (23%) |
MFI: metastasis-free interval, ECOG: Eastern Cooperative Oncology Group performance status, NLR: neutrophil/lymphocyte ratio, PLR: platelet/lymphocyte ratio, RDW: red cell distribution width, NR: not reached, NA: not available.